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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S160need revision later; overall health); support during recovery (3 items:
length of recovery; doctors’ recommendations; availability of
resources); and others’ opinions (3 items: surgery as last resort;
friends’/family's recommendations; considerations about others).
Controlling for age and education, results from the multiple linear
regression model suggested that women rated risks/beneﬁts (p¼0.01),
indications (p¼0.02), and support during recovery (p¼0.002) as more
important in TJA decision making than did men, but rated ‘others’
opinions’ similarly (p¼0.35).
Conclusions: Our results identiﬁed the importance of information about
TJA in four distinct domains: indications for TJA, risks and beneﬁts of
surgery, support during recovery, and others’ opinions. Further, our
ﬁndings indicate that, after controlling for age and level of education,
gender differences exist in TJA information needs. These ﬁndings will be
useful to inform TJA education and patient-physician decision making.
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USE OF DRUG COMBINATIONS IN PATIENTS WITH OSTEOARTHRITIS:
A POPULATION-BASED COHORT STUDY
D. Prieto-Alhambra y,z, N. Wilson x. yBotnar Res. Ctr., Univ. of Oxford,
Oxford, United Kingdom; zMRC Lifecourse Epidemiology Unit, Univ. of
Southampton, Southampton, United Kingdom; x Inst. of Bone and Joint
Res., Kolling Inst. of Med. Res., Royal North Shore Hosp., Sydney, Australia
Purpose: Patients affected with osteoarthritis (OA) use different drugs
in search for relief, with potential impact on patients’ safety and
healthcare costs. However, the use of drug combinations in these
patients has not been explored in detail.
We used a large database including primary care medical records and
pharmacy invoice data to explore use of the following drugs in OA
patients in the period 2006-2010: non-steroidal anti-inﬂammatory
drugs (NSAIDs), Symptomatic Slow Acting Drugs for OA (SYSADOA),
COX-2 inhibitors (COX2i), opioids, and other analgesics (paracetamol
and metamizol).
Methods: - Study population and setting: We screened the SIDIAP
Database (www.sidiap.org) to identify those aged 40 years or older with
a new diagnosis of OA using ICD-10 codes. Among these, we ascertained
prevalence of use of oral NSAIDs, COX2i, SYSADOA, opioids, and anal-
gesics (all alone and in combination) in the period 2006-2011.
- Source of data: SIDIAP contains anonymised medical records
and pharmacy invoice data of a representative >5 million
people in Catalonia (North-East Spain).
- Statistical analyses: We estimated prevalence (and 99% Conﬁ-
dence Intervals) of use of these drugs and their combinations,
and the proportion of occasional (MPR25%) and regular
(MPR50%) users for each of them.
Results: We identiﬁed 281,356 patients with an incident clinical diag-
nosis of OA. Among these, 128,314(45.6%) were treated with 3 or more
drugs, and 57,835(20.6%) with no subsidized drugs.
The 3 most common combinations of drugs were: oral NSAID+analgesic
(12.2%); 2.topical NSAID+analgesic (2.5%); and oral NSAID+SYSADOA
(1.8%). Besides, 34,672(12.3%) patients received only 1 drug, the 3 most
common being, in descending order: oral NSAID, analgesic and SYSADOA.
The proportions of occasional and regular users were highest for SYSA-
DOA (24.5% occasional and 6.9% regular users), and lowest for opioidsĂ(7.3% occasional and 1.9% regular users). Proportions (%) of occasional
and regular users for each drug of study are presented in Figure.
Conclusions: About 75% of OA patients are treated with at least 2 drugs,
and more than half receive 3 or more. However, compliance with these
drugs is very low, and hence consequences of polymedication on
effectiveness and safety are difﬁcult to predict as based on clinical trials
results.
These data are of interest for health care provision for patients with OA.
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THE CONSULTATION PREVALENCE OF OSTEOARTHRITIS 2030 MAY
INCREASE BY 50%: PROGNOSIS FOR SWEDEN
A. Turkiewicz y, I.F. Petersson y, J. Björk z, L.E. Dahlberg y, M.
Englund y,x. yDept. of Orthopedics, Clinical Sci. Lund, Lund, Sweden;
zDiv. of Occupational and Environmental Med., Lund Univ., Lund,
Sweden; xClinical Epidemiology Res. and Training Unit, Boston Univ. Sch.
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Purpose: To project the future consultation prevalence of osteoarthritis
(OA) in the knee, hip and hand.
Methods: The Skåne Health Care Register (SHCR) is a legislative,
mandatory register in Skåne County, Sweden (total population 1.3
million), based on physicians’ International Classiﬁcation of Diseases
(ICD) 10 diagnostic codes. We used observational data on the consul-
tation prevalence of the knee OA (M17), hip OA (M16) and hand/wrist
OA (M15.1, M15.2, M18, M19.0D, M19.1D, M19.2D) by the 31st Dec 2011Figure 1. The prognosis of OA consultation prevalence in knee, hip and hand in
Swedish adults (aged 20+).
